期刊文献+

含左氧氟沙星三联方案不同疗程治疗幽门螺杆菌的疗效观察 被引量:4

Efficacy and Safety of Triple Therapy of Levofloxacin in Different Courses for Helicobacter Pylori
下载PDF
导出
摘要 目的:评价含左氧氟沙星的三联方案治疗幽门螺杆菌的有效性和安全性及不同疗程的疗效。方法:将幽门螺旋杆菌(Helicobacter pylori,H pylori)阳性的患者263例随机分为克拉霉素治疗组和阿莫西林治疗组,各组按不同疗程分为5、7、10、14d亚组,两组联合的抗菌药均含左氧氟沙星,抑酸剂选用雷贝拉唑。各组在治疗前1周内和治疗后4~8周分别检测H pylori感染情况。结果:含左氧氟沙星的三联方案H pylori根除率为81.0%,克拉霉素治疗组H pylori根除率与阿莫西林治疗组比较无统计学差异(P〉0.05),随着疗程的增加根除率也增加,7、10、14d亚组要明显高于5d亚组,但10、14d亚组之间无统计学意义(P〉0.05);两组随着疗程的增加不良反应的发生率均增加,但克拉霉素组总的发生率要略高于阿莫西林组;在临床症状缓解方面,两组之间无统计学意义(P〉0.05),但各组随着疗程的增加缓解率也增加,但10d与14d亚组的临床症状缓解率之间无统计学意义(P〉0.05)。结论:含左氧氟沙星的雷贝拉唑联合克拉霉素或阿莫西林是安全有效的幽门螺杆菌根除方案,7、10、14d疗程均可获得好的疗效,综合根除率、不良反应发生率和临床症状缓解率,10d疗程最佳。 Objective: To evaluate the efficacy and safety of the triple with levofloxacin in different courses in the treatment of Helicobacter pylori.Methods: 263 cases of Helicobacter pylori-positive patients were randomly divided into amoxicillin treatment group and clarithromycin treatment group,each group is divided into different treatment subgroups by 5,7,10,14days.The two groups received the anti-bacterial drugs of levofloxacin and antacid of Rabeprazole.Before the treatment within one week and after the treatment in 4-8 weeks,Helicobacter pylori infection was detected.Results: Helicobacter pylori eradication rate was 81.0%;clarithromycin treatment group and amoxicillin treatment group showed no significant difference;With the course increase also increased the eradication rate of helicobacter pylori;7,10,14days subgroup was significantly higher than the 5-day subgroup;in the 10-day subgroup and 14-day subgroup there was no statistical significance;the incidence of adverse reactions increased with the course increase;clarithromycin group was slightly higher than the amoxicillin group;in clinical remission,there was no statistical significance between the two groups,but in each group with the increase in course,remission rate also increased;10-day and 14-day sub-group had no statistical significance in the remission rates of clinical symptoms.Conclusion: Rabeprazole levofloxacin with clarithromycin or amoxicillin joint is safe and effective for the eradication of H pylori.7,10,14days course can get a good effect.In terms of eradication,incidence of adverse reactions and remission of clinical symptoms,10-day course is seen as the best for treatment.
出处 《长江大学学报(自然科学版)》 CAS 2011年第6期147-149,159,共4页 Journal of Yangtze University(Natural Science Edition)
关键词 左氧氟沙星 幽门螺杆菌 三联疗法 Levofloxacin Helicobacter pylori Triple therapy
  • 相关文献

参考文献11

  • 1胡伏莲主编..幽门螺杆菌感染诊疗指南[M].北京:人民卫生出版社,2006:215.
  • 2Vakil N. Antimicrobial Resistance and Eradication Strategies for Helicobacter pylori [J] . Rev Gastroenterol Disord, 2009, 9 (3): 78-83. 被引量:1
  • 3Malfertheiner P, MegraudF, O'MorainC, etal. Current eoneepts in the management of Helicobaeter pyloriinfection: the Maastrieht Ⅲ Consensus Report [J].Gut, 2007, 56 (6): 772-81. 被引量:1
  • 4Ling T K, Cheng A F, Sung J J, et al. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study [J]. Helicobacter, 1996, 1: 57-61. 被引量:1
  • 5Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabepraz01e/levofloxacin-based triple therapies for Helicobacter pylori infection [J]. Aliment Pharmacol Ther, 2000, 14: 1339-1343. 被引量:1
  • 6Di Caro S, Zoeco M A, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori [J]. Eur J Gastroenterol Hepatol, 2002, 14: 1309-1312. 被引量:1
  • 7Pcrri F, Festa V, Merla A, et al. Randomized study of different 'econd-line' therapies for Helieobaeter pylori infection after failure of the standard'Maastricht triple therapy[J]. Aliment Pharmacol Ther, 2003, 18: 815-820. 被引量:1
  • 8Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxaein based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy [J] . Dig Liver Dis, 2003, 35:711-715. 被引量:1
  • 9Kawakami Y, Akahane T, Yamaguchi M, et aL In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori [J]. Antimicrob Agents Chemother, 2000, 44: 458-461. 被引量:1
  • 10舒建昌,杨冬华,张晓燕,宋慧东,庞春梅,杨绮红,黎铭恩,罗国彪,张文茹,汤绍辉.雷贝拉唑、克拉霉素、阿莫西林4日疗法根除幽门螺杆菌感染疗效观察[J].中国实用内科杂志,2003,23(5):305-306. 被引量:8

二级参考文献11

  • 1Luth S, Teyssen S, Kolbel CB, et al. 4-day triple therapy with rabeprazole,amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease - a pilot study. Z Gastroentero1,2001,39 (4):279-281,284-285. 被引量:1
  • 2Morii M ,Takata H ,Fujisaki H ,et al. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H + ,K( + ) -ATPase is correlatedwith the rate of acidactivation of the inhibitor. Biochem Pharmacol, 1990, 15,39(4):661-667. 被引量:1
  • 3Hirai M, Azuma T, ho S, et al. A proton pump iiLhibitor, E3810, has antibacterial activity through binding toHelicobacter pylori. J Gastroenterol.1995.30(4):461-464. 被引量:1
  • 4Park JB, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole.Biol Pharm Bull, 1996,19 (2):182-187. 被引量:1
  • 5Ishizaki T, Horai Y. Review article:cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmaeol Ther, 1999,13(Suppl 3):27-36. 被引量:1
  • 6WILLIAMS MP, POUNDER RE. Review artiele: the pharmacology of rabeprazole[J]. Aliment pharmacol Ther, 1999, 13(3): 3-10. 被引量:1
  • 7PARK JB, IMAMURA L, KOBASHI K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprezole[J]. Biol Pharm Bull, 1996, 19: 182-187. 被引量:1
  • 8KAWAKAMI. In vitro activities of rebeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with othe antimicrobials against recent clinical isolates of Helicobacter pylori Antimicrob Agents Chemother, 2000, 44:458-461. 被引量:1
  • 9BUZAS GM, IUYES G. Six regimens for the eradication of Helicobaeter pylori (Hp) in duodenal, ulcer patients: three consecutive trials (1995-1999)[J]. J Physiol Paris, 2001, 95(1-6): 437-441. 被引量:1
  • 10张万岱.幽门螺杆菌若干问题的共识意见[J].中华消化杂志,2000,20(2):117-118. 被引量:387

共引文献9

同被引文献39

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部